CN111918871A - 基于环戊烷的sting(干扰素基因刺激物)调节剂 - Google Patents

基于环戊烷的sting(干扰素基因刺激物)调节剂 Download PDF

Info

Publication number
CN111918871A
CN111918871A CN201980019494.9A CN201980019494A CN111918871A CN 111918871 A CN111918871 A CN 111918871A CN 201980019494 A CN201980019494 A CN 201980019494A CN 111918871 A CN111918871 A CN 111918871A
Authority
CN
China
Prior art keywords
cancer
compound
salt
nmr
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980019494.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·威思
I·J·麦卡尔平
R·帕特曼
E·Y·芮
A·芬萨姆
A·马代尔纳
M·贾莱
K·S·加吉瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN111918871A publication Critical patent/CN111918871A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980019494.9A 2018-03-15 2019-03-12 基于环戊烷的sting(干扰素基因刺激物)调节剂 Pending CN111918871A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US62/643,467 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US62/666,204 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US62/742,532 2018-10-08
US201962809990P 2019-02-25 2019-02-25
US62/809,990 2019-02-25
PCT/IB2019/052009 WO2019175776A1 (en) 2018-03-15 2019-03-12 Cyclopentane-based modulators of sting (stimulator of interferon genes)

Publications (1)

Publication Number Publication Date
CN111918871A true CN111918871A (zh) 2020-11-10

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980019494.9A Pending CN111918871A (zh) 2018-03-15 2019-03-12 基于环戊烷的sting(干扰素基因刺激物)调节剂

Country Status (25)

Country Link
US (4) US10538542B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765474B1 (cg-RX-API-DMAC7.html)
JP (1) JP7266942B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200131878A (cg-RX-API-DMAC7.html)
CN (1) CN111918871A (cg-RX-API-DMAC7.html)
AU (1) AU2019234043A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093631C (cg-RX-API-DMAC7.html)
CL (1) CL2020002352A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200382A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000160A (cg-RX-API-DMAC7.html)
EC (1) ECSP20057847A (cg-RX-API-DMAC7.html)
ES (1) ES2923298T3 (cg-RX-API-DMAC7.html)
IL (1) IL277278A (cg-RX-API-DMAC7.html)
MA (1) MA52012A (cg-RX-API-DMAC7.html)
MX (1) MX2020009587A (cg-RX-API-DMAC7.html)
NI (1) NI202000058A (cg-RX-API-DMAC7.html)
PE (1) PE20210412A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551486A1 (cg-RX-API-DMAC7.html)
PY (1) PY1919127A (cg-RX-API-DMAC7.html)
RU (1) RU2020130048A (cg-RX-API-DMAC7.html)
SG (1) SG11202008102VA (cg-RX-API-DMAC7.html)
TW (1) TWI741268B (cg-RX-API-DMAC7.html)
UY (1) UY38145A (cg-RX-API-DMAC7.html)
WO (1) WO2019175776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
PH12022550709A1 (en) * 2019-09-25 2023-03-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
EP4259642A1 (en) * 2020-12-08 2023-10-18 F. Hoffmann-La Roche AG Novel synthesis of phosphorodithioate oligonucleotides
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459131A (zh) * 2014-06-04 2017-02-22 葛兰素史克知识产权开发有限公司 作为sting调节剂的环状二核苷酸
CN107108684A (zh) * 2015-01-29 2017-08-29 葛兰素史克知识产权开发有限公司 尤其用于治疗癌症的环状二核苷酸

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459131A (zh) * 2014-06-04 2017-02-22 葛兰素史克知识产权开发有限公司 作为sting调节剂的环状二核苷酸
CN107108684A (zh) * 2015-01-29 2017-08-29 葛兰素史克知识产权开发有限公司 尤其用于治疗癌症的环状二核苷酸

Also Published As

Publication number Publication date
ECSP20057847A (es) 2021-04-29
KR20200131878A (ko) 2020-11-24
PE20210412A1 (es) 2021-03-04
WO2019175776A1 (en) 2019-09-19
CR20200382A (es) 2020-12-10
JP7266942B2 (ja) 2023-05-01
US10538542B2 (en) 2020-01-21
MX2020009587A (es) 2020-10-05
EP3765474A1 (en) 2021-01-20
US10968242B2 (en) 2021-04-06
PH12020551486A1 (en) 2021-08-23
US20190284216A1 (en) 2019-09-19
PY1919127A (es) 2020-08-26
CA3093631A1 (en) 2019-09-19
CA3093631C (en) 2023-01-24
ES2923298T3 (es) 2022-09-26
RU2020130048A (ru) 2022-04-15
TWI741268B (zh) 2021-10-01
US20200102334A1 (en) 2020-04-02
CL2020002352A1 (es) 2020-12-18
IL277278A (en) 2020-10-29
MA52012A (fr) 2021-01-20
NI202000058A (es) 2021-01-08
BR112020018593A2 (pt) 2020-12-29
AU2019234043A1 (en) 2020-09-17
US20230382932A1 (en) 2023-11-30
DOP2020000160A (es) 2020-09-30
JP2021518335A (ja) 2021-08-02
SG11202008102VA (en) 2020-09-29
UY38145A (es) 2019-10-31
TW201945036A (zh) 2019-12-01
EP3765474B1 (en) 2022-06-15
RU2020130048A3 (cg-RX-API-DMAC7.html) 2022-04-15
US20210230196A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US10968242B2 (en) Cyclopentane-based modulators of STING (stimulator of interferon genes)
ES2623794T3 (es) Intermedios para la preparación de moduladores de receptores tipo toll
AU2017247798B2 (en) Heterocyclic amides useful as protein modulators
JP5675614B2 (ja) 医薬組成物用のチエノピリミジン
EP3728283B1 (en) 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018212788A1 (en) Cyclic dinucleotides as STING agonists
JP2021502383A (ja) Sting調節剤化合物、ならびに製造及び使用する方法
WO2014124430A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
TW200524606A (en) Nucleoside compounds for treating viral infections
EP3873484B1 (en) Novel sting agonists
CN102438626A (zh) 具有Aurora A选择性抑制作用的新型氨基吡啶衍生物
CN109694397B (zh) 环状二核苷酸化合物、其制备方法和应用
WO2019052359A1 (zh) 双杂环三氮唑核苷类似物的抗肿瘤作用与应用
HK40031084A (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
KR20230107586A (ko) 다기능성 사이클릭 디뉴클레오티드 및 이의 용도
OA19842A (en) Cyclopentane-based modulators of sting (stimulator of interferon genes).
AU2015203139B2 (en) Modulators of toll-like receptors
TWI675664B (zh) Hcv聚合酶抑制劑
TW201620923A (zh) Hcv聚合酶抑制劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031084

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201110

WD01 Invention patent application deemed withdrawn after publication